Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparing the Effects of Topical Miltefosine and Glucantime in Treatment of Cutaneous Leishmaniasis



Asilian A1 ; Omrani S2 ; Nilforoushzadeh MA3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin Disease and Leishmaniasis Research Center, Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Isfahan Medical School Published:2014

Abstract

Background: Due to the limited number of studies, failure to adequately investigating the impact of miltefosine in the treatment of cutaneous leishmaniasis, and the fact that faster recovery of injuries causes less scarring for the patient, the present study aimed to investigate the effect of topical miltefosine on the treatment of cutaneous leishmaniasis. Methods: In this clinical trial study, 64 patients with cutaneous leishmaniasis were equally treated in two groups with miltefosine and Glucantime. The first group of patients was treated with localized Glucantime 2 times a week (up to 28 days) and the second group was treated with localized miltefosine (ointment 6%), once daily (for 28 days), in a way that the lesion was completely smeared with the ointment. Patients were examined every week during treatment and the lesion size was recorded. All the patients' lesions regarding their appearance, wound size, induration, erythema, and lesion size during weekly visits, at end of the treatment, and one month after the treatment were assessed. Findings: Mean age of the patients was 23.12 ± 13.30 years. The cure rate was 34.4% in patients treated with topical Glucantime, and 53.1% in the patients treated with topical miltefosine (P = 0.010). 1 month after the treatment, the cure rate was 50% in patients treated with topical Glucantime, and 81.3% in patients treated with miltefosine (P = 0.300). Mean size of the remaining scar caused by cutaneous leishmaniasis was 1.9 cm in the group treated with Glucantime, and 0.9 cm in the group treated with miltefosine (P = 0.001). Conclusion: According to the results of this study and other studies in this area, it can be concluded that topical miltefosine can treat the lesions faster than intralesional Glucantime injection. In addition, patients treated with topical miltefosine had smaller scars.
Related Docs
View other Related Docs
1. The Skin Side Effects of Topical Glucantime in Patients With Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2015)
2. Effect of Combination Therapy With Systemic Glucantime and Pentoxifylline in the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2006)
3. Comparison of Healing Effects of Local Injection of Glucantime With or Without Trichloroacetic Acid 50% in Cutaneous Leshmaniasis, Journal of Isfahan Medical School (2009)
4. The Efficacy of Intralesional Meglumine Antimoniate (Glucantime) Versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2012)
5. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran, Archives of Iranian Medicine (2020)
6. Comparative Effect of Topical Trichloroacetic Acid and Intralesional Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, International Journal of Pharmacology (2006)
7. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2013)
8. The Efficacy of 5% Trichloroacetic Acid Cream in the Treatment of Cutaneous Leishmaniasis Lesions, Journal of Dermatological Treatment (2012)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (47)
Ali Asilian (15)
Other Related Docs
9. Treatment of Acute Cutaneous Leishmaniasis With Intralesional Injection of Meglumine Antimoniate: Comparison of Conventional Technique With Mesotherapy Gun, International Journal of Dermatology (2010)
10. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
11. Treatment of Cutaneous Leishmaniasis With Either Topical Paromomycin or Intralesional Meglumine Antimoniate, Clinical and Experimental Dermatology (2003)
12. Efficacy of Local Heat Therapy by Radiofrequency in the Treatment of Cutaneous Leishmaniasis, Compared With Intralesional Injection of Meglumine Antimoniate, Clinical and Experimental Dermatology (2007)
13. Epidemiology and Clinical Features of Cutaneous Leishmaniasis in Badrood City, Iran, in 2013, Journal of Isfahan Medical School (2015)
14. Cutaneous Leishmaniasis Reinfection: Skin Disease and Leishmaniasis Research Center, Isfahan, Iran, Journal of Isfahan Medical School (2015)
15. The Effects of Prednisolone and Mometasone on Wound Healing Caused by Leishmania Major in Balb/C Mice, Journal of Isfahan Medical School (2020)
16. The Efficacy of Treatment With Intralesional Meglumine Antimoniate Alone, Compared With That of Cryotherapy Combined With the Meglumine Antimoniate or Intralesional Sodium Stibogluconate, in the Treatment of Cutaneous Leishmaniasis, Annals of Tropical Medicine and Parasitology (2003)
17. Comparison Between the Efficacy of Photodynamic Therapy and Topical Paromomycin in the Treatment of Old World Cutaneous Leishmaniasis: A Placebo-Controlled, Randomized Clinical Trial, Clinical and Experimental Dermatology (2006)
18. Treatment of Recurrent Cutaneous Leishmaniasis, International Journal of Dermatology (1995)
19. A Comparison of the Effects of Topical Injection of Glucantime Plus Glycolic Acid 70% and Salicylic Acid 20% With Topical Injection of Glucantime Alone in the Treatment of Acute Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2017)
20. Successful Treatment of Lupoid Cutaneous Leishmaniasis With Glucantime and Topical Trichloroacetic Acid (A Case Report), Korean Journal of Parasitology (2008)
21. Comparison Between the Efficacy of Photodynamic Therapy and Topical Paromomycin in the Treatment of Old World Cutaneous Leishmaniasis: A Placebo-Controlled, Randomized Clinical Trial, Indian Journal of Dermatology (2006)
22. The Efficacy of Achillea Millefolium Topical Gel Along With Intralesional Injection of Glucantime in the Treatment of Acute Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2012)
23. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
24. Development of Liposomes Loaded With Anti-Leishmanial Drugs for the Treatment of Cutaneous Leishmaniasis, Journal of Liposome Research (2013)
25. Antimonial Treatment Failure Rate in Patients With Cutaneous Leishmaniasis, Tehran University Medical Journal (2018)
26. Efficacy of Paromomycin Ointment in the Treatment of Cutaneous Leishmaniasis: Results of a Double-Blind, Randomized Trial in Isfahan, Iran, Annals of Tropical Medicine and Parasitology (2005)
27. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
28. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Itraconazole in the Treatment of Cutaneous Leishmaniasis, Journal of the European Academy of Dermatology and Venereology (2005)
29. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Carbon Dioxide Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Dermatology Research and Practice (2016)
30. Comparison Between the Efficacy of Photodynamic Therapy and Topical Paromomycin in the Treatment of Old World Cutaneous Leishmaniasis: A Placebo-Controlled, Randomized Clinical Trial, Journal of Isfahan Medical School (2012)
31. Efficacy of Adjunctive Topical Liposomal Clarithromycin on Systemic Glucantime in Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Frontiers in Pharmacology (2023)
32. Treatment of Cutaneous Leishmaniasis With Ketoconazole Cream, Journal of Dermatological Treatment (2003)
33. Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask, Journal of Isfahan Medical School (2013)
34. Isolation of Bacteria Causing Secondary Bacterial Infection in the Lesions of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2008)
35. Evaluation of Leishmanin Skin Test and Its Relationship With the Clinical Form and Duration of Cutaneous Leishmaniasis, Dermatology Online Journal (2006)
36. Evaluation of Leishmanin Skin Test Reaction in Different Variants of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2013)
37. Effect of Topical Honey Application Along With Intralesional Injection of Glucantime in the Treatment of Cutaneous Leishmaniasis, BMC Complementary and Alternative Medicine (2007)
38. Effect of Adjunctive Topical Liposomal Azithromycin on Systemic Azithromycin on Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Iranian Journal of Pharmaceutical Research (2021)
39. Heat Therapy for Cutaneous Leishmaniasis: A Literature Review, Journal of Research in Medical Sciences (2021)
40. Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, Dermatology (2004)
41. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
42. Treatment of Cutaneous Leishmaniasis: Cassia Fistula Fruit Gel-Intralesional Glucantime Vs. Placebo Gel- Intralesional Glucantime Combination, Tehran University Medical Journal (2010)
43. Topical Effectiveness of Different Concentrations of Nanosilver Solution on Leishmania Major Lesions in Balb/C Mice, Journal of Vector Borne Diseases (2012)
44. Comparative Study of the Efficacy of Combined Cryotherapy and Intralesional Meglumine Antimoniate (Glucantime®) Vs. Cryotherapy and Intralesional Meglumine Antimoniate (Glucantime®) Alone for the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2004)
45. Treatment of Cutaneous Leishmaniasis With Aminosidine (Paromomycin) Ointment: Double-Blind, Randomized Trial in the Islamic Republic of Iran, Bulletin of the World Health Organization (2003)
46. A Comparative Study Between the Efficacy of Systemic Meglumine Antimoniate Therapy With Standard or Low Dose Plus Oral Omeprazole in the Treatment of Cutaneous Leishmaniasis, Journal of Vector Borne Diseases (2008)
47. The Effect of Intralesional Meglumine Antimoniate (Glucantime) Versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions, Journal of Research in Medical Sciences (2012)
48. Pcr-Rflp Diagnosis and Characterization of Leishmania Species Causing Human Cutaneous Leishmaniasis and Evaluation of Treatment Times With Glucantime in These Patients, Tropical Biomedicine (2016)
49. Distribution Frequency of Pathogenic Bacteria Isolated From Cutaneus Leishmaniasis Lesions, Korean Journal of Parasitology (2008)
50. A Randomized, Placebo-Controlled Trial of a Two-Week Regimen of Aminosidine (Paromomycin) Ointment for Treatment of Cutaneous Leishmaniasis in Iran, American Journal of Tropical Medicine and Hygiene (1995)